The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria

NCT01871753 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2019-07-18

No results posted yet for this study

Summary

The purpose of this study is to compare antibiotics versus no-treatment in kidney transplant recipients with asymptomatic bacteriuria.

Conditions

Interventions

OTHER

Anti-Infective Agents

10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)

Sponsors & Collaborators

  • University Hospital, Lille

    collaborator OTHER
  • Universitair Ziekenhuis Brussel

    collaborator OTHER
  • Hôpital Necker Enfants-Malades, Université de Paris Descartes, APHP, France

    collaborator UNKNOWN
  • Centre Hospitalier Universitaire Brugmann

    collaborator OTHER
  • Centre Hospitalier Universitaire de Charleroi

    collaborator OTHER
  • University Ghent

    collaborator OTHER
  • Centre Hospitalier Epicura, Belgium

    collaborator UNKNOWN
  • University of Liege

    collaborator OTHER
  • Nantes University Hospital

    collaborator OTHER
  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Julien Coussement, MD · Hôpital Universitaire Erasme, Brussels, Belgium

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01871753 on ClinicalTrials.gov